A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

计划入组 600 人 · 首次发布于 2025 年 5 月 25 日

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

计划入组 300 人 · 首次发布于 2025 年 5 月 30 日

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

计划入组 40 人 · 首次发布于 2006 年 12 月 5 日

Diabetic macular edema(RevOpsis)

Uveitic macular edema(RevOpsis)

ST-102

RIGHT TO CARE

South Africa

Power to Decide

United States

Partnership to End Addiction

United States

Kodiak Sciences to Present Final Phase 1b Results for KSI-101 in Macular Edema Secondary to Inflammation

Kodiak Sciences Completes Enrollment in First Pivotal Cohort of Phase 3 PEAK Trial for KSI-101 in Macular Edema Secondary to Inflammation

Kodiak Sciences' Tarcocimab Shows Promise in Phase 3 Retinal Disease Trials, Analyst Upgrades Stock